AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03265405
Drug: Medium dose prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An initial dose of 40 mg/day will be administered for 4 weeks, followed by 30 mg/day for 4 weeks, 20 mg/day for 4 weeks, 15 mg/day for 4 weeks, 10 mg/day for 4 weeks, and 5 mg/day for 4 weeks, after which the drug will be tapered over 2 weeks and discontinued.
Trial: NCT01343706
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for oral administration
Trial: NCT01343706
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate release solid oral dosage (film-coated tablet)
Trial: NCT03285477
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle Ointment was used in participants with Clinically typical AK on the face or scalp.
Trial: NCT03285477
Drug: KX2-391 Ointment 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The experimental drug, KX2-391 Ointment 1% was used in participants with Clinically typical AK on the face or scalp.
Trial: NCT01590641
Drug: Single Ascending Dose (SAD) Cohorts GS-9620
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Single Ascending Dose (SAD) Cohorts will receive a single dose of GS-9620.
Trial: NCT01590641
Drug: Multiple Ascending Dose (MAD) Cohorts
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Multiple Ascending Dose (MAD) Cohorts will receive GS-9620 once weekly for two weeks (QW x 2 doses)
Trial: NCT01693445
Drug: OIS (Oxaliplatin, Irinotecan, S-1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose level 1 treatment will be delivered as a 2-week cycle as bellows;~1. Oxaliplatin 85 mg/m²IV on day 1~2. Irinotecan 120 mg/m² IV on day 1~3. S-1 60 mg/m2/day PO on day 1-7~Dose escalation will be continued until more than one-third of the patients in a given cohort show dose limiting toxicities (DLT) during treatment cycle 1. If at least 2 patients are observed to have DLT, this dose level is defined as the maximum tolerated dose (MTD). If exactly 1 of the 3 patients treated show DLT, 3 additional patients are treated at the current dose level.
Trial: NCT02103686
Drug: Experimental drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sustained release formulation of pregabalin
Trial: NCT00221364
Drug: Mass treatment with oral azithromycin to an entire village
RxNorm normalized name: Aldex AN
DrugBank: Doxylamine (DB00366)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04781075
Drug: Exparel Injectable Product
RxNorm normalized name: Exparel Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given at the beginning of the surgery for post-operative pain management
Trial: NCT03124459
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant fusion protein or buffer solution
Trial: NCT00317044
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice daily
Trial: NCT00430118
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00430118
Drug: mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00430118
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00270894
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: cyclophosphamide (600 mg/m\^2) every 2 weeks for 4 cycles
Trial: NCT03933943
Drug: LY3361237
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT03933943
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT01070329
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received placebo QD, po for 8 weeks, followed by placebo QD, po during the 2-week taper phase.
Trial: NCT02154646
Drug: LY2157299
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT03576144
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple rising inhaled doses
Trial: NCT02318095
Drug: Adjuvant chemotheapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy may be given after surgery at the clinical discretion of the medical oncologist
Trial: NCT02071940
Drug: PLX3397
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLX3397 capsules 1000mg/day as monotherapy
Trial: NCT00686127
Drug: Placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 patch was applied topically to the affected site(s) for 12 hours each day.
Trial: NCT00220363
Drug: SPM 907
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01046812
Drug: Caphosol
RxNorm normalized name: Caphosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caphosol 2-4 times daily oral rinse for two weeks duration minimum up to one month.
Trial: NCT01552057
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo taken orally once every day for 15 weeks
Trial: NCT01451593
Drug: Phenytoin
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenytoin will be loaded using at total dose of 15mg/kg (rounded to the nearest 100mg) divided into three equal doses given once daily for 3 days.This will be followed by a daily maintenance dose of 4mg/kg once a day (rounded up to the nearest 50mg, with a maximum dose of 300mg)for 13 weeks.Phenytoin levels will be taken at 1 and 3 months.
Trial: NCT01451593
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo identical in appearance to active IMP (phenytoin)
Trial: NCT02119715
Drug: Pegylated rhG-CSF 100μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were administered pegylated rhG-CSF 100 ug/kg once at the 3rd day of 2 to 4 chemotherapy cycle(epirubicin 75mg/m2+docetaxel 75mg/m2 for neoadjuvant therapy and epirubicin 100mg/m2+cyclophosphamide 600mg/m2 for adjuvant therapy).
Trial: NCT02119715
Drug: Pegylated rhG-CSF:150 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were administered pegylated rhG-CSF 150 ug/kg once at the 3rd day of 2 to 4 chemotherapy cycle(epirubicin 75mg/m2+docetaxel 75mg/m2 for neoadjuvant therapy and epirubicin 100mg/m2+cyclophosphamide 600mg/m2 for adjuvant therapy).
Trial: NCT02119715
Drug: rhG-CSF 5 μg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were administered rhG-CSF 5 ug/kg daily during chemotherapy cycle(epirubicin 75mg/m2+docetaxel 75mg/m2 for neoadjuvant therapy and epirubicin 100mg/m2+cyclophosphamide 600mg/m2 for adjuvant therapy) until (1)continuous injection for 14 days (2)two successive ANC counts exceed 5.0×109/L（3）ANC counts exceed 15×109/L at anytime.
Trial: NCT01784887
Drug: Procellera
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PROCELLERA TM is an FDA-cleared bioelectrical dressing delivered in a sterile, single layer sheet consisting of a flexible polyester fabric layer containing silver and zinc, which are held in position on the polyester with a biocompatible binder.
Trial: NCT03115996
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo
Trial: NCT02582996
Drug: Acetaminophen+Caffeine+Dihydroergotamine+Metoclopramide.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subject must manage 02 tablets of Cefalium right after a moderate to severe migraine.
Trial: NCT02582996
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subject must manage 02 tablets of Tylenol right after a moderate to severe migraine.
Trial: NCT00358657
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00460382
Drug: Optimized background regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NRTIs and or enfuvirtide (investigator choice)
Trial: NCT00928070
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo sham 4 mg and 8 mg
Trial: NCT01849926
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01381055
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with cutaneous leishmaniasis treated with pentavalent antimony/metilglucamine 20mg/kg/day during 20 days and placebo pills three times a day during 20 days.
Trial: NCT02752828
Drug: Oral anti-diabetic drugs
RxNorm normalized name: Diabetic Tussin EX Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: tablet~Route of administration: oral
Trial: NCT04807894
Drug: Vaginal Cream with Applicator
RxNorm normalized name: Amino-Cerv, vaginal cream with applicator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal testosterone 300-μg dose will be compounded with 13.5 mg of testosterone propionate in 0.45 mL of polysorbate National Formulary liquid and sufficient emollient cream base to make 45 g total. A calibrated vaginal applicator will be supplied to measure out doses of 1 g each. All study medications will be compounded by a single pharmacy so as to avoid variation in compounding between pharmacies and allow for control of compounding. Randomization will be conducted by the compounding pharmacy to allow for double-blinding of patients and clinicians.
Trial: NCT04472728
Drug: BIO101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIO101 capsules
Trial: NCT04472728
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo capsules
Trial: NCT00640094
Drug: melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive a total intravenous melatonin dose of 12 mg + intracoronary melatonin dose of 2 mg. The intravenous dose will be distributed in a volume of 50 ml of a isotonic and sterile solution and administered by intravenous infusion during 60 minutes. The intracoronary dose will be distributed in a volume of 10 ml of a isotonic and sterile solution and administered as a bolus.
Trial: NCT02786901
Drug: Vehicle Gel
RxNorm normalized name: vehicle gel base no.61
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel
Trial: NCT02013544
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02013544
Drug: Prasterone (DHEA)
RxNorm normalized name: prasterone (DHEA)
DrugBank: Prasterone sulfate (DB05804)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02183714
Drug: Songha Night ®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02183714
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00673595
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The pharmacy will prepare tablets that match the varenicline tablets. The tablets should be taken orally after food intake with 200 ml of water.
Trial: NCT00733525
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg/day of fluoxetine, which can be incrementally increased to 80 mg/day
Trial: NCT01748799
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants received the same interventions (Fixed or Self-Titrated Placebo), just in different sequences.
Trial: NCT00516919
Drug: Xenical + behavioral intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg TID; Behavioral weight loss in Spanish
Trial: NCT02494180
Drug: fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: arm A receiving iv fentanyl
Trial: NCT01955616
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05019586
Drug: levofloxacin, amoxicillin, clarithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy of Helicobacter pylori including two antibiotics and a proton inhibitor for 10 days
Trial: NCT02276495
Drug: Local infiltration - 100 mLs of a solution containing: Ropivacaine + Epinephrine + Ketorolac + Clonidine + 0.9% Normal saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mLs of a solution containing:~Ropivacaine 2 mg/mL (49.25 mL) + Epinephrine 1 mg/mL (0.5 mL) + Ketorolac 30mg/mL (1mL) + Clonidine 100 mcg/mL (0.8 mL) + 0.9% Normal saline (48.45 mL)
Trial: NCT00682656
Drug: Glucantime®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15mg Sb+5/Kg/day, during 20 days. Maximum dose:15ml/day
Trial: NCT00682656
Drug: Zithromax ®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zithromax ®/ Pfizer, 500 mg - 1x day, during 20 days
Trial: NCT01166165
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 placebo tablets daily for 20 weeks
Trial: NCT00885079
Drug: OPC-12759 Ophthalmic suspension
RxNorm normalized name: Opcon-A Ophthalmic Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPC-12759 Ophthalmic suspension 2%
Trial: NCT00850746
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT00312455
Drug: Pro-eicosapentaenoic acid (EPA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 450 mg 5x/day
Trial: NCT00312455
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 capsules/day
Trial: NCT01082484
Drug: NaCl 0.9%
RxNorm normalized name: DEXTROSE 5%/NACL 0.9% INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cutaneous iontophoresis at 20 microA/ 100 microA during 20 min
Trial: NCT01272583
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo, once daily for six weeks
Trial: NCT00709202
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03512236
Drug: BC Pram Ins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of BC Pram Ins
Trial: NCT03512236
Drug: Symlin® and Humulin®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of pramlintide and human insulin
Trial: NCT03512236
Drug: Humalog®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of lispro
Trial: NCT03512236
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of 0.9% NaCl
Trial: NCT00646659
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02670395
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution will be administered orally.
Trial: NCT03862755
Drug: Chemoprophylaxis with Low Molecular Weight Heparin (LMWH)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early chemoprophylaxis means low-molecular weight heparin (LMWH) 3075 IU (WHO Units) injection subcutaneously one time a day no later than 24 hours after surgery. Early ambulation means activity out of bed no later than 24 hours after surgery. According to different risk level, patients received different thromboprophylaxis strategies. Early ambulation alone was for patients at low risk (Caprini 0-4), early chemoprophylaxis plus early ambulation was for patients at moderate (Caprini 5-8) or high risk (Caprini ≥9).
Trial: NCT03880877
Drug: Leucovorin and 5-FU
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period)
Trial: NCT04109066
Drug: anthracycline
RxNorm normalized name: Anthracycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on Specified days
Trial: NCT04109066
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on Specified days
Trial: NCT04109066
Drug: Endocrine Therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Variable endocrine therapy of investigators choice
Trial: NCT00138762
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00787111
Drug: Fluoxetine (prozac)
RxNorm normalized name: fluoxetine Oral Capsule [Prozac]
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Formulation: ODT
Trial: NCT04363216
Drug: Ascorbic Acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascor® ascorbic acid 2-hour infusion daily (for 6 days), escalating dose (0.3g/kg, 0.6g/kg, 0.9g/kg).
Trial: NCT02695940
Drug: LEO 124249 ointment 30 mg/g
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00709826
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo: 100 mg tablets, 400 mg/day
Trial: NCT02368470
Drug: Standard triple therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole (Rabiet®, ildong pharmaceutical Co. Ltd., Seoul, Korea) 20 mg twice daily, amoxicillin (Pamoxin®, Dongwha Co. Ltd., Seoul, Korea) 1 g twice daily, and clarithromycin (Klaricid®, Abbot Korea Co. Ltd., Seoul, Korea) 500 mg twice daily for 7 days
Trial: NCT03445702
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill manufactured to mimic metformin 1000mg
Trial: NCT01941589
Drug: oral 5-ASA+/-topical 5-ASA+IV corticosteroids / PO Methylprednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: maximal oral 5-ASA+/-topical 5-ASA+IV corticosteroids
Trial: NCT01479348
Drug: [F-18]-5-FLUORO-2'-DEOXYCYTIDINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18FdCyd radiotracer
Trial: NCT01479348
Drug: Tetrahydrouridine intravenous (IV)
RxNorm normalized name: (4R)-2'-Deoxy-2',2'-difluoro-3,4,5,6-tetrahydrouridine
DrugBank: Cedazuridine (DB15694)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total dose of THU = 350 mg/m\^2, IV
Trial: NCT01420770
Drug: SAR302503
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:capsule~Route of administration: oral
Trial: NCT03246529
Drug: BL-8040 1.25 mg/kg + G-CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up to 2 subcutaneous (SC) injections of BL-8040 are anticipated during the study. Injections of G-CSF per standard of care
Trial: NCT01284504
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg tablet oral
Trial: NCT01781455
Drug: BBI503
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03041311
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo IV
Trial: NCT03211013
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single-dose administration of placebo nasal spray, complete computer-based tasks post-dose for approximately 1 hour
Trial: NCT00166790
Drug: chemotherapy agents
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03049449
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 300 or 500 mg/m\^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3
Trial: NCT01073579
Drug: Sabril®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infantile Spasms (IS): Initiate therapy at 50 mg/kg/day twice daily increasing total daily dose per instructions to a maximum of 150 mg/kg/day.~Refractory Complex Partial Seizures (rCPS) in Adults: Initiate therapy at 500 mg twice daily, increasing total daily dose per instructions. The recommended dose is 1.5 grams twice daily.
Trial: NCT00386841
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03093402
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will self-administer JBT-101 placebo by mouth (orally), at prescribed dose and frequency per protocol, Days 1-84. Administration of dose(s) should be at least 8 hours apart.
Trial: NCT01636492
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose
Trial: NCT02886702
Drug: TAZORAC® (tazarotene) Cream 0.05%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAZORAC® (tazarotene) Cream 0.05% to cover only the lesions with a thin film.
Trial: NCT02886702
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (vehicle of the test product) to cover only the lesions with a thin film.
Trial: NCT03633279
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: an equinitrogenous amount of lactoalbumin 2.1 grams, and equicaloric amount with 4.0 g saccharose and 3.0 g mannitol for a total of 33.6 kcal/packet.(one packet at 6pm and two at 9pm)
Trial: NCT06056947
Drug: EVEGYN A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EVEGYN A: Fixed-dose combination of 600 mg fenticonazole nitrate + 1000 mg tinidazole + 100 mg lidocaine vaginal ovule Single dose, single administration (1x1)
Trial: NCT06056947
Drug: EVEGYN B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EVEGYN B: Fixed-dose combination of 600 mg fenticonazole nitrate + 2000 mg tinidazole + 100 mg lidocaine vaginal ovule Single dose, single administration (1x1)
Trial: NCT06056947
Drug: Gynomax® XL Vaginal Ovule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg tioconazole + 300 mg tinidazole + 100 mg lidocaine single dose / day, during three consecutive days (1x1 / 3 days)